NeuroOne Medical Technologies Grants Inducement Equity Award to New Employee

NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) announced on June 25, 2026, that its independent directors approved an equity award to a new employee as a material inducement for employment. The grant, effective June 24, 2026, was made under the company's 2021 Inducement Plan and disclosed in accordance with Nasdaq Listing Rule 5635(c)(4), which requires public announcement of awards not approved by stockholders.

The new hire, who was not a previous employee or director, received an option to purchase 10,000 shares of NeuroOne's common stock at an exercise price of $3.27 per share, equaling the closing price on the grant date. The option has a ten-year term and vests over four years, with 25% vesting on June 24, 2027, and the remainder in 12 equal quarterly installments, contingent on continued employment and subject to acceleration or forfeiture under certain conditions.

This inducement grant highlights NeuroOne's strategy to attract key talent in the competitive medical technology sector. The company focuses on surgical solutions for neurological disorders, with FDA-cleared products including Evo® Cortical Electrodes, Evo® sEEG Electrodes, the OneRF® Ablation System for brain procedures, and the OneRF® Trigeminal Nerve Ablation System. These offerings aim to reduce hospitalizations, lower costs, and improve patient outcomes through diagnostic and therapeutic functions.

NeuroOne continues research and development in drug delivery, basivertebral nerve ablation, and spinal cord stimulation. The company's commitment to innovation is reflected in its inducement awards, which align new hires' interests with shareholder value. For more information, visit nmtc1.com.

The grant underscores the importance of equity incentives in attracting specialized talent in the medical device industry. As NeuroOne expands its product pipeline and market presence, such awards may become more common, emphasizing the company's growth trajectory and need for expertise in neurosurgery and neuromodulation.